<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771615</url>
  </required_header>
  <id_info>
    <org_study_id>111729</org_study_id>
    <nct_id>NCT00771615</nct_id>
  </id_info>
  <brief_title>Immunogenicity &amp; Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years</brief_title>
  <official_title>A Trial to Evaluate the Safety &amp; Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK
      1557484A is immunogenic when given to adults aged 18-64 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All enrolled subjects will receive 1 dose of study vaccine. All subjects will attend formal
      study center visits for safety and immunogenicity assessments on Days 0, 10, 42, 84, and 182
      with a telephone safety contact on Day 364.

      This Protocol Posting has been updated according to Protocol amendment, 8 Dec 08
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain.</measure>
    <time_frame>At Day 10</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) titer less than (&lt;) 1:10 for HI and a post-vaccination reciprocal titer greater than or equal to (≥) 1:40, or a pre-vaccination reciprocal titer ≥ 1:10 for HI and at least a 4-fold increase in post-vaccination reciprocal titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain</measure>
    <time_frame>At Day 10</time_frame>
    <description>A seroprotected subject against the A/turkey virus strain was defined as a subject with serum HI antibody reciprocal titer ≥ 1:40 post-vaccination, a level of HI antibodies that may correlate with benefit in protection against influenza.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain.</measure>
    <time_frame>At Day 10</time_frame>
    <description>HI antibody titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strains.</measure>
    <time_frame>At Day 0 to Day 42 and at Day 0 to Day 182</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) titer less than (&lt;) 1:10 for HI and a post-vaccination reciprocal titer greater than or equal to (≥) 1:40, or a pre-vaccination reciprocal titer ≥ 1:10 for HI and at least a 4-fold increase in post-vaccination reciprocal titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers Against the A/Turkey/Turkey/1/2005 Virus Strain.</measure>
    <time_frame>At Day 0, Day 10, Day 42 and Day 182</time_frame>
    <description>Titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Geometric Mean Fold Rise (GMFR) Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain.</measure>
    <time_frame>At Day 0 to Day 10, Day 42 and Day 182</time_frame>
    <description>GMFR were defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Titers Against the A/Indonesia/5/2005 (A/Indo) Virus Strain.</measure>
    <time_frame>At Day 0, Day 10, Day 42 and Day 182</time_frame>
    <description>Titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against the A/Indonesia/5/2005 (A/Indo) and A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strains.</measure>
    <time_frame>At Day 0, Day 10, Day 42 and Day 182 for A/Indo and at Day 0, Day 42 and Day 182 for A/turkey virus strains.</time_frame>
    <description>A seroprotected subject was defined as a subject with serum HI antibody reciprocal titer ≥ 1:40 post-vaccination, a level of HI antibodies that may correlate with benefit in protection against influenza.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Indonesia/5/2005 (A/Indo) Virus Strains.</measure>
    <time_frame>At Day 0 to Day 10, Day 42 and Day 182</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer less than (&lt;) 1:10 and a post-vaccination reciprocal titer greater than or equal to (≥) 1:40 or a pre-vaccination reciprocal titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Geometric Mean Fold Rise (GMFR) Against the A/Indonesia/5/2005 (A/Indo) Virus Strains.</measure>
    <time_frame>At Day 10, Day 42 and Day 182</time_frame>
    <description>GMFR were defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microneutralization (MN) Antibody Titers Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</measure>
    <time_frame>At Day 0, Day 10, Day 42 and Day 182</time_frame>
    <description>MN antibody titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for MN Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</measure>
    <time_frame>At Day 0, Day 10, Day 42 and Day 182</time_frame>
    <description>A seropositive subject was defined as a vaccinated subject who had a MN antibody titer ≥ the cut-off value of 1:28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</measure>
    <time_frame>At Day 10</time_frame>
    <description>VRR was defined as a 4-fold rise from a detectable baseline titer or a rise from undetectable (&lt; 1:28, recorded 1:14 if &lt; 1:28) to ≥ 1:56 in the subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains</measure>
    <time_frame>At Day 42</time_frame>
    <description>VRR was defined as a 4-fold rise from a detectable baseline titer or a rise from undetectable (&lt; 1:28, recorded 1:14 if &lt; 1:28) to ≥ 1:56 in the subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</measure>
    <time_frame>At Day 182</time_frame>
    <description>VRR was defined as a 4-fold rise from a detectable baseline titer or a rise from undetectable (&lt; 1:28, recorded 1:14 if &lt; 1:28) to ≥ 1:56 in the subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</measure>
    <time_frame>Within the 7-day (Days 0-6) post vaccination period.</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any solicited local symptoms regardless of their intensity grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms.</measure>
    <time_frame>Within the 7-day (Days 0-6) post vaccination period.</time_frame>
    <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location (joint pain), muscle aches, shivering, sweating and fever. Any =occurrence of any solicited general symptoms reported irrespective of intensity grade and relationship to vaccination. Any fever = oral temperature ≥ 38.0 degrees Celsius (°C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Medically-attended Adverse Events (MAEs).</measure>
    <time_frame>From Day 0 to Day 378</time_frame>
    <description>MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any was defined as any occurrence of MAE(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Unsolicited Adverse Events (AEs).</measure>
    <time_frame>From Day 0 to Day 42</time_frame>
    <description>An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.&quot;Any&quot; was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs).</measure>
    <time_frame>From Day 0 to Day 378</time_frame>
    <description>A SAE was defined as any untoward medical occurrence that: resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">469</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>A/turkey H5N1 influenza Formulation A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/turkey H5N1 influenza Formulation B1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/turkey H5N1 influenza Formulation B2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/turkey H5N1 influenza Formulation C1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/turkey H5N1 influenza Formulation C2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/turkey H5N1 influenza Formulation D1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/turkey H5N1 influenza Formulation D2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/turkey H5N1 influenza Formulation E1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/turkey H5N1 influenza Formulation E2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK A/turkey H5N1 Influenza vaccine</intervention_name>
    <description>One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.</description>
    <arm_group_label>A/turkey H5N1 influenza Formulation E1 Group</arm_group_label>
    <arm_group_label>A/turkey H5N1 influenza Formulation A Group</arm_group_label>
    <arm_group_label>A/turkey H5N1 influenza Formulation C2 Group</arm_group_label>
    <arm_group_label>A/turkey H5N1 influenza Formulation D2 Group</arm_group_label>
    <arm_group_label>A/turkey H5N1 influenza Formulation B2 Group</arm_group_label>
    <arm_group_label>A/turkey H5N1 influenza Formulation C1 Group</arm_group_label>
    <arm_group_label>A/turkey H5N1 influenza Formulation D1 Group</arm_group_label>
    <arm_group_label>A/turkey H5N1 influenza Formulation E2 Group</arm_group_label>
    <arm_group_label>A/turkey H5N1 influenza Formulation B1 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults 18 to 64 years of age at time of first vaccination, inclusive.

          -  Written informed consent obtained from the subject.

          -  Stable health status as defined by absence of a health event satisfying the definition
             of a SAE, or a change in an ongoing drug therapy due to therapeutic failure or
             symptoms of drug toxicity, within 1 month prior to enrollment.

          -  Access to a consistent means of telephone contact, which may be either in the home or
             at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user
             device.

          -  Comprehension of the study requirements, expressed availability for the required study
             period, and ability to attend scheduled visits.

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol.

        Exclusion Criteria:

          -  Presence of evidence of substance abuse or of neurological or psychiatric diagnoses
             which, even if clinically stable, are deemed by the investigator to render the
             potential subject unable/unlikely to provide accurate safety reports.

          -  Diagnosed with cancer, or treatment for cancer, within 3 years.

          -  Presence of an oral temperature &gt;= 37.8ºC, or acute symptoms greater than &quot;mild&quot;
             severity on the scheduled date of vaccination.

          -  Any confirmed or suspected immunosuppressive or immunodeficiency condition including
             history of human immunodeficiency virus (HIV) infection.

          -  Receipt of systemic glucocorticoids (prednisone &gt;= 10 mg/day for more than 14
             consecutive days) within 1 month prior to study enrollment, or any other cytotoxic or
             immunosuppressive drug within 6 months of study enrollment.

          -  An acute evolving neurological disorder or history of Guillain-Barré syndrome within 6
             weeks of receipt of seasonal influenza vaccine.

          -  Any significant disorder of coagulation or treatment with Coumadin derivatives or
             heparin.

          -  Administration of any vaccines within 30 days before the first study vaccine dose.

          -  Previous administration of any H5N1 vaccine.

          -  Use of any investigational or non-registered product (drug or vaccine) or planned
             participation in another investigational study within 30 days prior to study
             enrollment, or during the 12 months following test article administration. Use of any
             investigational or non-registered product with immunosuppressive properties is
             exclusionary at any time during the trial.

          -  Receipt of any immunoglobulins and/or any blood products within 3 months of study
             enrollment or planned administration of any of these products during the study period.

          -  Any known or suspected allergy to any constituent of influenza vaccines; a history of
             anaphylactic-type reaction to consumption of eggs; or a history of severe adverse
             reaction to a previous influenza vaccine.

          -  Known pregnancy or a positive urine beta-human chorionic gonadotropin (β-hCG) test
             result prior to vaccination.

          -  Lactating or nursing.

          -  Women of child bearing potential (who lack a history of reliable contraceptive
             practices. The provision of this history does NOT replace the requirement to perform,
             and obtain negative results in pregnancy urine tests prior to vaccination.

          -  Known receipt of analgesic or antipyretic medication with the specific intent of
             prophylaxis of vaccine reactogenicity on the day of vaccination. Subjects on stable
             chronic regimens of potentially analgesic or anti-pyretic medications for pre-existing
             diagnoses are not required to discontinue them.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <results_first_submitted>December 19, 2013</results_first_submitted>
  <results_first_submitted_qc>August 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2014</results_first_posted>
  <disposition_first_submitted>July 2, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 2, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 7, 2010</disposition_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human</keyword>
  <keyword>Avian</keyword>
  <keyword>safety</keyword>
  <keyword>vaccines</keyword>
  <keyword>influenza</keyword>
  <keyword>pandemic</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>H5N1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111729</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111729</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111729</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111729</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111729</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111729</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111729</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A/Turkey H5N1 Influenza Formulation A Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>A/Turkey H5N1 Influenza Formulation B1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>A/Turkey H5N1 Influenza Formulation B2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>A/Turkey H5N1 Influenza Formulation C1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P5">
          <title>A/Turkey H5N1 Influenza Formulation C2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P6">
          <title>A/Turkey H5N1 Influenza Formulation D1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P7">
          <title>A/Turkey H5N1 Influenza Formulation D2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P8">
          <title>A/Turkey H5N1 Influenza Formulation E1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P9">
          <title>A/Turkey H5N1 Influenza Formulation E2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="61"/>
                <participants group_id="P7" count="46"/>
                <participants group_id="P8" count="59"/>
                <participants group_id="P9" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48">Up to Day 364</participants>
                <participants group_id="P2" count="70">Up to Day 364</participants>
                <participants group_id="P3" count="40">Up to Day 364</participants>
                <participants group_id="P4" count="59">Up to Day 364</participants>
                <participants group_id="P5" count="40">Up to Day 364</participants>
                <participants group_id="P6" count="60">Up to Day 364</participants>
                <participants group_id="P7" count="45">Up to Day 364</participants>
                <participants group_id="P8" count="58">Up to Day 364</participants>
                <participants group_id="P9" count="41">Up to Day 364</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A/Turkey H5N1 Influenza Formulation A Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>A/Turkey H5N1 Influenza Formulation B1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>A/Turkey H5N1 Influenza Formulation B2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>A/Turkey H5N1 Influenza Formulation C1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>A/Turkey H5N1 Influenza Formulation C2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B6">
          <title>A/Turkey H5N1 Influenza Formulation D1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B7">
          <title>A/Turkey H5N1 Influenza Formulation D2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B8">
          <title>A/Turkey H5N1 Influenza Formulation E1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B9">
          <title>A/Turkey H5N1 Influenza Formulation E2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="60"/>
            <count group_id="B5" value="40"/>
            <count group_id="B6" value="61"/>
            <count group_id="B7" value="46"/>
            <count group_id="B8" value="59"/>
            <count group_id="B9" value="41"/>
            <count group_id="B10" value="469"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="11.47"/>
                    <measurement group_id="B2" value="40.6" spread="12.02"/>
                    <measurement group_id="B3" value="41.1" spread="11.82"/>
                    <measurement group_id="B4" value="41.2" spread="12.33"/>
                    <measurement group_id="B5" value="41.1" spread="12.46"/>
                    <measurement group_id="B6" value="42.4" spread="11.15"/>
                    <measurement group_id="B7" value="41.2" spread="9.78"/>
                    <measurement group_id="B8" value="40.6" spread="12.01"/>
                    <measurement group_id="B9" value="41.6" spread="11.60"/>
                    <measurement group_id="B10" value="41.3" spread="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="31"/>
                    <measurement group_id="B8" value="37"/>
                    <measurement group_id="B9" value="19"/>
                    <measurement group_id="B10" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="22"/>
                    <measurement group_id="B10" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain.</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) titer less than (&lt;) 1:10 for HI and a post-vaccination reciprocal titer greater than or equal to (≥) 1:40, or a pre-vaccination reciprocal titer ≥ 1:10 for HI and at least a 4-fold increase in post-vaccination reciprocal titer.</description>
        <time_frame>At Day 10</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain.</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) titer less than (&lt;) 1:10 for HI and a post-vaccination reciprocal titer greater than or equal to (≥) 1:40, or a pre-vaccination reciprocal titer ≥ 1:10 for HI and at least a 4-fold increase in post-vaccination reciprocal titer.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="127"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="57"/>
                    <measurement group_id="O5" value="56"/>
                    <measurement group_id="O6" value="122"/>
                    <measurement group_id="O7" value="108"/>
                    <measurement group_id="O8" value="51"/>
                    <measurement group_id="O9" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain</title>
        <description>A seroprotected subject against the A/turkey virus strain was defined as a subject with serum HI antibody reciprocal titer ≥ 1:40 post-vaccination, a level of HI antibodies that may correlate with benefit in protection against influenza.</description>
        <time_frame>At Day 10</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain</title>
          <description>A seroprotected subject against the A/turkey virus strain was defined as a subject with serum HI antibody reciprocal titer ≥ 1:40 post-vaccination, a level of HI antibodies that may correlate with benefit in protection against influenza.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="127"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="127"/>
                    <measurement group_id="O7" value="111"/>
                    <measurement group_id="O8" value="69"/>
                    <measurement group_id="O9" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain.</title>
        <description>HI antibody titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:10.</description>
        <time_frame>At Day 10</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Haemagglutination Inhibition (HI) Antibody Titers Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain.</title>
          <description>HI antibody titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:10.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="127"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229.6" lower_limit="148.6" upper_limit="354.9"/>
                    <measurement group_id="O2" value="847.3" lower_limit="686.1" upper_limit="1046.4"/>
                    <measurement group_id="O3" value="810.5" lower_limit="666.6" upper_limit="985.3"/>
                    <measurement group_id="O4" value="121.9" lower_limit="89.7" upper_limit="165.7"/>
                    <measurement group_id="O5" value="86.9" lower_limit="64.7" upper_limit="116.7"/>
                    <measurement group_id="O6" value="838.5" lower_limit="703.1" upper_limit="1000.1"/>
                    <measurement group_id="O7" value="819.8" lower_limit="647.8" upper_limit="1037.3"/>
                    <measurement group_id="O8" value="97.9" lower_limit="70.3" upper_limit="136.4"/>
                    <measurement group_id="O9" value="108.6" lower_limit="82.3" upper_limit="143.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strains.</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) titer less than (&lt;) 1:10 for HI and a post-vaccination reciprocal titer greater than or equal to (≥) 1:40, or a pre-vaccination reciprocal titer ≥ 1:10 for HI and at least a 4-fold increase in post-vaccination reciprocal titer.</description>
        <time_frame>At Day 0 to Day 42 and at Day 0 to Day 182</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strains.</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) titer less than (&lt;) 1:10 for HI and a post-vaccination reciprocal titer greater than or equal to (≥) 1:40, or a pre-vaccination reciprocal titer ≥ 1:10 for HI and at least a 4-fold increase in post-vaccination reciprocal titer.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/turkey , D 42 (N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="123"/>
                    <measurement group_id="O3" value="108"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="123"/>
                    <measurement group_id="O7" value="108"/>
                    <measurement group_id="O8" value="45"/>
                    <measurement group_id="O9" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey, D 182 (N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="103"/>
                    <measurement group_id="O7" value="92"/>
                    <measurement group_id="O8" value="31"/>
                    <measurement group_id="O9" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers Against the A/Turkey/Turkey/1/2005 Virus Strain.</title>
        <description>Titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:10</description>
        <time_frame>At Day 0, Day 10, Day 42 and Day 182</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Haemagglutination Inhibition (HI) Antibody Titers Against the A/Turkey/Turkey/1/2005 Virus Strain.</title>
          <description>Titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:10</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/turkey , D 0 (N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.0" upper_limit="7.5"/>
                    <measurement group_id="O2" value="13.5" lower_limit="11.3" upper_limit="16.3"/>
                    <measurement group_id="O3" value="14.4" lower_limit="11.6" upper_limit="18.0"/>
                    <measurement group_id="O4" value="14.2" lower_limit="11.3" upper_limit="17.9"/>
                    <measurement group_id="O5" value="10.9" lower_limit="8.7" upper_limit="13.6"/>
                    <measurement group_id="O6" value="14.1" lower_limit="11.6" upper_limit="17.2"/>
                    <measurement group_id="O7" value="13.7" lower_limit="11.1" upper_limit="16.9"/>
                    <measurement group_id="O8" value="13.2" lower_limit="10.3" upper_limit="17.1"/>
                    <measurement group_id="O9" value="11.8" lower_limit="9.6" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey, D 10 (N=47; 126;113;84;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229.6" lower_limit="148.6" upper_limit="354.9"/>
                    <measurement group_id="O2" value="847.3" lower_limit="686.1" upper_limit="1046.4"/>
                    <measurement group_id="O3" value="810.5" lower_limit="666.6" upper_limit="985.3"/>
                    <measurement group_id="O4" value="121.9" lower_limit="89.7" upper_limit="165.7"/>
                    <measurement group_id="O5" value="86.9" lower_limit="64.7" upper_limit="116.7"/>
                    <measurement group_id="O6" value="838.5" lower_limit="703.1" upper_limit="1000.1"/>
                    <measurement group_id="O7" value="819.8" lower_limit="647.8" upper_limit="1037.3"/>
                    <measurement group_id="O8" value="97.9" lower_limit="70.3" upper_limit="136.4"/>
                    <measurement group_id="O9" value="108.6" lower_limit="82.3" upper_limit="143.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 42 (N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.4" lower_limit="102.1" upper_limit="236.3"/>
                    <measurement group_id="O2" value="652.2" lower_limit="525.3" upper_limit="809.8"/>
                    <measurement group_id="O3" value="699.5" lower_limit="561.9" upper_limit="870.8"/>
                    <measurement group_id="O4" value="126.3" lower_limit="91.6" upper_limit="174.1"/>
                    <measurement group_id="O5" value="81.4" lower_limit="59.6" upper_limit="111.2"/>
                    <measurement group_id="O6" value="653.9" lower_limit="545.5" upper_limit="783.9"/>
                    <measurement group_id="O7" value="697.8" lower_limit="539.2" upper_limit="903.2"/>
                    <measurement group_id="O8" value="90.9" lower_limit="64.7" upper_limit="127.6"/>
                    <measurement group_id="O9" value="113.6" lower_limit="84.1" upper_limit="153.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="26.8" upper_limit="62.4"/>
                    <measurement group_id="O2" value="221.5" lower_limit="172.3" upper_limit="284.6"/>
                    <measurement group_id="O3" value="238.4" lower_limit="185.1" upper_limit="307.0"/>
                    <measurement group_id="O4" value="62.7" lower_limit="44.9" upper_limit="87.5"/>
                    <measurement group_id="O5" value="42.9" lower_limit="31.6" upper_limit="58.3"/>
                    <measurement group_id="O6" value="213.3" lower_limit="170.5" upper_limit="266.9"/>
                    <measurement group_id="O7" value="249.1" lower_limit="187.6" upper_limit="330.8"/>
                    <measurement group_id="O8" value="51.1" lower_limit="37.2" upper_limit="70.3"/>
                    <measurement group_id="O9" value="53.2" lower_limit="38.3" upper_limit="73.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Geometric Mean Fold Rise (GMFR) Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain.</title>
        <description>GMFR were defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.</description>
        <time_frame>At Day 0 to Day 10, Day 42 and Day 182</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Geometric Mean Fold Rise (GMFR) Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain.</title>
          <description>GMFR were defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/turkey, D 10(N=47;126;113;84;;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" lower_limit="23.3" upper_limit="59.9"/>
                    <measurement group_id="O2" value="61.6" lower_limit="47.4" upper_limit="80.1"/>
                    <measurement group_id="O3" value="56.3" lower_limit="43.5" upper_limit="72.8"/>
                    <measurement group_id="O4" value="8.5" lower_limit="6.0" upper_limit="12.1"/>
                    <measurement group_id="O5" value="8.0" lower_limit="6.0" upper_limit="10.7"/>
                    <measurement group_id="O6" value="58.4" lower_limit="45.5" upper_limit="74.9"/>
                    <measurement group_id="O7" value="59.8" lower_limit="45.5" upper_limit="78.6"/>
                    <measurement group_id="O8" value="7.4" lower_limit="5.2" upper_limit="10.5"/>
                    <measurement group_id="O9" value="9.1" lower_limit="6.8" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 42(47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" lower_limit="16.6" upper_limit="38.5"/>
                    <measurement group_id="O2" value="48.2" lower_limit="37.2" upper_limit="62.5"/>
                    <measurement group_id="O3" value="48.6" lower_limit="37.5" upper_limit="63.0"/>
                    <measurement group_id="O4" value="8.9" lower_limit="6.2" upper_limit="12.9"/>
                    <measurement group_id="O5" value="7.5" lower_limit="5.6" upper_limit="10.1"/>
                    <measurement group_id="O6" value="46.3" lower_limit="36.2" upper_limit="59.2"/>
                    <measurement group_id="O7" value="50.9" lower_limit="38.6" upper_limit="67.1"/>
                    <measurement group_id="O8" value="6.9" lower_limit="4.8" upper_limit="9.8"/>
                    <measurement group_id="O9" value="9.6" lower_limit="7.1" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="4.4" upper_limit="10.0"/>
                    <measurement group_id="O2" value="16.4" lower_limit="12.4" upper_limit="21.5"/>
                    <measurement group_id="O3" value="16.6" lower_limit="12.7" upper_limit="21.6"/>
                    <measurement group_id="O4" value="4.4" lower_limit="3.0" upper_limit="6.3"/>
                    <measurement group_id="O5" value="3.9" lower_limit="2.9" upper_limit="5.2"/>
                    <measurement group_id="O6" value="15.1" lower_limit="11.6" upper_limit="19.6"/>
                    <measurement group_id="O7" value="18.2" lower_limit="13.7" upper_limit="24.1"/>
                    <measurement group_id="O8" value="3.9" lower_limit="2.7" upper_limit="5.4"/>
                    <measurement group_id="O9" value="4.4" lower_limit="3.2" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Titers Against the A/Indonesia/5/2005 (A/Indo) Virus Strain.</title>
        <description>Titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:10</description>
        <time_frame>At Day 0, Day 10, Day 42 and Day 182</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Titers Against the A/Indonesia/5/2005 (A/Indo) Virus Strain.</title>
          <description>Titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:10</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indo, D 0 (N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="5.6" upper_limit="9.4"/>
                    <measurement group_id="O2" value="26.1" lower_limit="20.8" upper_limit="32.7"/>
                    <measurement group_id="O3" value="23.8" lower_limit="18.6" upper_limit="30.5"/>
                    <measurement group_id="O4" value="25.5" lower_limit="19.3" upper_limit="33.7"/>
                    <measurement group_id="O5" value="18.5" lower_limit="13.9" upper_limit="24.5"/>
                    <measurement group_id="O6" value="25.5" lower_limit="20.2" upper_limit="32.1"/>
                    <measurement group_id="O7" value="24.5" lower_limit="19.2" upper_limit="31.1"/>
                    <measurement group_id="O8" value="22.0" lower_limit="16.6" upper_limit="29.1"/>
                    <measurement group_id="O9" value="21.7" lower_limit="16.3" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo , D 10 (N=47;126;113;84;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286.5" lower_limit="187.6" upper_limit="437.5"/>
                    <measurement group_id="O2" value="905.0" lower_limit="743.7" upper_limit="1101.4"/>
                    <measurement group_id="O3" value="888.6" lower_limit="739.6" upper_limit="1067.5"/>
                    <measurement group_id="O4" value="176.7" lower_limit="131.9" upper_limit="236.8"/>
                    <measurement group_id="O5" value="113.6" lower_limit="83.2" upper_limit="155.1"/>
                    <measurement group_id="O6" value="873.5" lower_limit="738.5" upper_limit="1033.3"/>
                    <measurement group_id="O7" value="924.9" lower_limit="745.0" upper_limit="1148.1"/>
                    <measurement group_id="O8" value="124.6" lower_limit="89.4" upper_limit="173.8"/>
                    <measurement group_id="O9" value="161.3" lower_limit="122.3" upper_limit="212.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo , D 42 (N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.3" lower_limit="129.3" upper_limit="286.1"/>
                    <measurement group_id="O2" value="740.8" lower_limit="604.7" upper_limit="907.4"/>
                    <measurement group_id="O3" value="798.1" lower_limit="656.6" upper_limit="970.1"/>
                    <measurement group_id="O4" value="168.7" lower_limit="123.5" upper_limit="230.5"/>
                    <measurement group_id="O5" value="108.8" lower_limit="77.7" upper_limit="152.4"/>
                    <measurement group_id="O6" value="728.1" lower_limit="613.5" upper_limit="864.1"/>
                    <measurement group_id="O7" value="814.6" lower_limit="646.3" upper_limit="1026.8"/>
                    <measurement group_id="O8" value="107.8" lower_limit="75.6" upper_limit="153.8"/>
                    <measurement group_id="O9" value="169.3" lower_limit="126.1" upper_limit="227.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo , D182 (N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" lower_limit="22.6" upper_limit="53.6"/>
                    <measurement group_id="O2" value="213.8" lower_limit="166.4" upper_limit="274.6"/>
                    <measurement group_id="O3" value="224.2" lower_limit="174.4" upper_limit="288.3"/>
                    <measurement group_id="O4" value="58.7" lower_limit="41.2" upper_limit="83.6"/>
                    <measurement group_id="O5" value="38.6" lower_limit="28.0" upper_limit="53.3"/>
                    <measurement group_id="O6" value="197.3" lower_limit="156.0" upper_limit="249.5"/>
                    <measurement group_id="O7" value="246.0" lower_limit="188.0" upper_limit="321.9"/>
                    <measurement group_id="O8" value="42.7" lower_limit="30.4" upper_limit="60.0"/>
                    <measurement group_id="O9" value="53.4" lower_limit="37.9" upper_limit="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against the A/Indonesia/5/2005 (A/Indo) and A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strains.</title>
        <description>A seroprotected subject was defined as a subject with serum HI antibody reciprocal titer ≥ 1:40 post-vaccination, a level of HI antibodies that may correlate with benefit in protection against influenza.</description>
        <time_frame>At Day 0, Day 10, Day 42 and Day 182 for A/Indo and at Day 0, Day 42 and Day 182 for A/turkey virus strains.</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against the A/Indonesia/5/2005 (A/Indo) and A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strains.</title>
          <description>A seroprotected subject was defined as a subject with serum HI antibody reciprocal titer ≥ 1:40 post-vaccination, a level of HI antibodies that may correlate with benefit in protection against influenza.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indo , D 0 (N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="68"/>
                    <measurement group_id="O7" value="58"/>
                    <measurement group_id="O8" value="34"/>
                    <measurement group_id="O9" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo , D 10(N=47;126;113;84;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="68"/>
                    <measurement group_id="O6" value="127"/>
                    <measurement group_id="O7" value="111"/>
                    <measurement group_id="O8" value="69"/>
                    <measurement group_id="O9" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo , D 42(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="129"/>
                    <measurement group_id="O7" value="110"/>
                    <measurement group_id="O8" value="66"/>
                    <measurement group_id="O9" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo , D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="121"/>
                    <measurement group_id="O7" value="101"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 0(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="31"/>
                    <measurement group_id="O8" value="23"/>
                    <measurement group_id="O9" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 42(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="129"/>
                    <measurement group_id="O7" value="110"/>
                    <measurement group_id="O8" value="64"/>
                    <measurement group_id="O9" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="53"/>
                    <measurement group_id="O6" value="122"/>
                    <measurement group_id="O7" value="103"/>
                    <measurement group_id="O8" value="54"/>
                    <measurement group_id="O9" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Indonesia/5/2005 (A/Indo) Virus Strains.</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer less than (&lt;) 1:10 and a post-vaccination reciprocal titer greater than or equal to (≥) 1:40 or a pre-vaccination reciprocal titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
        <time_frame>At Day 0 to Day 10, Day 42 and Day 182</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Indonesia/5/2005 (A/Indo) Virus Strains.</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer less than (&lt;) 1:10 and a post-vaccination reciprocal titer greater than or equal to (≥) 1:40 or a pre-vaccination reciprocal titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indo, D 10 (N=47;126;113;84;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="108"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="122"/>
                    <measurement group_id="O7" value="108"/>
                    <measurement group_id="O8" value="41"/>
                    <measurement group_id="O9" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 42 (N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="121"/>
                    <measurement group_id="O7" value="104"/>
                    <measurement group_id="O8" value="38"/>
                    <measurement group_id="O9" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 182 (N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="96"/>
                    <measurement group_id="O7" value="79"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Geometric Mean Fold Rise (GMFR) Against the A/Indonesia/5/2005 (A/Indo) Virus Strains.</title>
        <description>GMFR were defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.</description>
        <time_frame>At Day 10, Day 42 and Day 182</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Geometric Mean Fold Rise (GMFR) Against the A/Indonesia/5/2005 (A/Indo) Virus Strains.</title>
          <description>GMFR were defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indo, D 10(N=47;126;113;84;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" lower_limit="24.8" upper_limit="62.4"/>
                    <measurement group_id="O2" value="34.7" lower_limit="26.8" upper_limit="44.8"/>
                    <measurement group_id="O3" value="37.3" lower_limit="28.5" upper_limit="48.8"/>
                    <measurement group_id="O4" value="6.8" lower_limit="4.9" upper_limit="9.5"/>
                    <measurement group_id="O5" value="6.1" lower_limit="4.5" upper_limit="8.3"/>
                    <measurement group_id="O6" value="34.3" lower_limit="26.8" upper_limit="43.8"/>
                    <measurement group_id="O7" value="37.8" lower_limit="28.5" upper_limit="50.2"/>
                    <measurement group_id="O8" value="5.7" lower_limit="4.1" upper_limit="7.9"/>
                    <measurement group_id="O9" value="7.3" lower_limit="5.4" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 42(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" lower_limit="17.2" upper_limit="40.5"/>
                    <measurement group_id="O2" value="28.4" lower_limit="22.0" upper_limit="36.7"/>
                    <measurement group_id="O3" value="33.5" lower_limit="25.4" upper_limit="44.3"/>
                    <measurement group_id="O4" value="6.6" lower_limit="4.7" upper_limit="9.4"/>
                    <measurement group_id="O5" value="5.9" lower_limit="4.3" upper_limit="8.1"/>
                    <measurement group_id="O6" value="28.6" lower_limit="22.3" upper_limit="36.6"/>
                    <measurement group_id="O7" value="33.3" lower_limit="24.9" upper_limit="44.5"/>
                    <measurement group_id="O8" value="4.9" lower_limit="3.4" upper_limit="7.0"/>
                    <measurement group_id="O9" value="7.8" lower_limit="5.7" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="3.1" upper_limit="7.4"/>
                    <measurement group_id="O2" value="8.2" lower_limit="6.3" upper_limit="10.7"/>
                    <measurement group_id="O3" value="9.4" lower_limit="7.2" upper_limit="12.3"/>
                    <measurement group_id="O4" value="2.3" lower_limit="1.6" upper_limit="3.3"/>
                    <measurement group_id="O5" value="2.1" lower_limit="1.6" upper_limit="2.8"/>
                    <measurement group_id="O6" value="7.7" lower_limit="6.0" upper_limit="9.9"/>
                    <measurement group_id="O7" value="10.1" lower_limit="7.6" upper_limit="13.4"/>
                    <measurement group_id="O8" value="1.9" lower_limit="1.4" upper_limit="2.7"/>
                    <measurement group_id="O9" value="2.5" lower_limit="1.8" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microneutralization (MN) Antibody Titers Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</title>
        <description>MN antibody titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:28.</description>
        <time_frame>At Day 0, Day 10, Day 42 and Day 182</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Microneutralization (MN) Antibody Titers Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</title>
          <description>MN antibody titers were expressed as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off of ≥ 1:28.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/turkey , D0(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="20.6" upper_limit="36.7"/>
                    <measurement group_id="O2" value="115.4" lower_limit="92.7" upper_limit="143.7"/>
                    <measurement group_id="O3" value="114.6" lower_limit="91.0" upper_limit="144.4"/>
                    <measurement group_id="O4" value="102.9" lower_limit="82.4" upper_limit="128.4"/>
                    <measurement group_id="O5" value="94.9" lower_limit="71.0" upper_limit="126.9"/>
                    <measurement group_id="O6" value="115.0" lower_limit="92.4" upper_limit="143.2"/>
                    <measurement group_id="O7" value="115.1" lower_limit="91.3" upper_limit="145.0"/>
                    <measurement group_id="O8" value="95.9" lower_limit="73.8" upper_limit="124.6"/>
                    <measurement group_id="O9" value="101.9" lower_limit="79.2" upper_limit="130.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 10(N=47;126;113;84;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2211.5" lower_limit="1579.1" upper_limit="3097.1"/>
                    <measurement group_id="O2" value="5367.7" lower_limit="4604.3" upper_limit="6257.6"/>
                    <measurement group_id="O3" value="5191.4" lower_limit="4403.4" upper_limit="6120.5"/>
                    <measurement group_id="O4" value="1276.2" lower_limit="962.5" upper_limit="1692.1"/>
                    <measurement group_id="O5" value="976.0" lower_limit="740.6" upper_limit="1286.1"/>
                    <measurement group_id="O6" value="5670.5" lower_limit="4958.4" upper_limit="6484.8"/>
                    <measurement group_id="O7" value="4876.8" lower_limit="4057.3" upper_limit="5861.7"/>
                    <measurement group_id="O8" value="1026.9" lower_limit="756.6" upper_limit="1393.9"/>
                    <measurement group_id="O9" value="1213.4" lower_limit="939.3" upper_limit="1567.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 42(N=47;128;113;85;79;129;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1582.9" lower_limit="1080.4" upper_limit="2319.0"/>
                    <measurement group_id="O2" value="4777.7" lower_limit="4037.3" upper_limit="5654.0"/>
                    <measurement group_id="O3" value="4649.4" lower_limit="3884.9" upper_limit="5564.3"/>
                    <measurement group_id="O4" value="1261.2" lower_limit="950.0" upper_limit="1674.2"/>
                    <measurement group_id="O5" value="906.0" lower_limit="673.6" upper_limit="1218.6"/>
                    <measurement group_id="O6" value="4915.6" lower_limit="4212.6" upper_limit="5735.8"/>
                    <measurement group_id="O7" value="4498.4" lower_limit="3699.9" upper_limit="5469.2"/>
                    <measurement group_id="O8" value="935.7" lower_limit="688.9" upper_limit="1271.0"/>
                    <measurement group_id="O9" value="1223.9" lower_limit="929.0" upper_limit="1612.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349.7" lower_limit="246.2" upper_limit="496.7"/>
                    <measurement group_id="O2" value="1509.9" lower_limit="1230.5" upper_limit="1852.8"/>
                    <measurement group_id="O3" value="1484.8" lower_limit="1181.6" upper_limit="1865.8"/>
                    <measurement group_id="O4" value="471.5" lower_limit="352.2" upper_limit="631.3"/>
                    <measurement group_id="O5" value="342.2" lower_limit="254.8" upper_limit="459.7"/>
                    <measurement group_id="O6" value="1375.0" lower_limit="1123.6" upper_limit="1682.7"/>
                    <measurement group_id="O7" value="1653.6" lower_limit="1313.4" upper_limit="2081.9"/>
                    <measurement group_id="O8" value="332.3" lower_limit="245.2" upper_limit="450.3"/>
                    <measurement group_id="O9" value="484.8" lower_limit="365.7" upper_limit="642.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 0(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" lower_limit="52.0" upper_limit="101.9"/>
                    <measurement group_id="O2" value="326.0" lower_limit="280.2" upper_limit="379.3"/>
                    <measurement group_id="O3" value="300.2" lower_limit="256.7" upper_limit="351.1"/>
                    <measurement group_id="O4" value="343.4" lower_limit="288.8" upper_limit="408.2"/>
                    <measurement group_id="O5" value="262.0" lower_limit="220.9" upper_limit="310.9"/>
                    <measurement group_id="O6" value="308.1" lower_limit="263.0" upper_limit="361.0"/>
                    <measurement group_id="O7" value="320.1" lower_limit="276.3" upper_limit="371.0"/>
                    <measurement group_id="O8" value="288.1" lower_limit="238.3" upper_limit="348.3"/>
                    <measurement group_id="O9" value="313.7" lower_limit="267.3" upper_limit="368.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 10(N=47;126;113;85;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2311.5" lower_limit="1708.9" upper_limit="3126.5"/>
                    <measurement group_id="O2" value="5807.1" lower_limit="5144.8" upper_limit="6554.7"/>
                    <measurement group_id="O3" value="5680.0" lower_limit="4943.7" upper_limit="6525.9"/>
                    <measurement group_id="O4" value="1516.5" lower_limit="1194.5" upper_limit="1925.3"/>
                    <measurement group_id="O5" value="1250.0" lower_limit="1002.6" upper_limit="1558.5"/>
                    <measurement group_id="O6" value="6011.0" lower_limit="5424.1" upper_limit="6661.5"/>
                    <measurement group_id="O7" value="5460.9" lower_limit="4670.2" upper_limit="6385.4"/>
                    <measurement group_id="O8" value="1240.9" lower_limit="966.2" upper_limit="1593.7"/>
                    <measurement group_id="O9" value="1523.4" lower_limit="1233.4" upper_limit="1881.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 42(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1622.0" lower_limit="1105.2" upper_limit="2380.4"/>
                    <measurement group_id="O2" value="5080.1" lower_limit="4412.0" upper_limit="5849.3"/>
                    <measurement group_id="O3" value="5054.1" lower_limit="4276.6" upper_limit="5972.8"/>
                    <measurement group_id="O4" value="1537.2" lower_limit="1192.0" upper_limit="1982.3"/>
                    <measurement group_id="O5" value="1194.5" lower_limit="940.0" upper_limit="1517.9"/>
                    <measurement group_id="O6" value="5157.1" lower_limit="4518.4" upper_limit="5886.0"/>
                    <measurement group_id="O7" value="4967.0" lower_limit="4163.2" upper_limit="5926.0"/>
                    <measurement group_id="O8" value="1178.0" lower_limit="916.6" upper_limit="1514.0"/>
                    <measurement group_id="O9" value="1552.4" lower_limit="1216.5" upper_limit="1981.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.8" lower_limit="267.5" upper_limit="542.1"/>
                    <measurement group_id="O2" value="1482.3" lower_limit="1223.3" upper_limit="1796.1"/>
                    <measurement group_id="O3" value="1556.0" lower_limit="1265.4" upper_limit="1913.3"/>
                    <measurement group_id="O4" value="535.5" lower_limit="416.8" upper_limit="688.0"/>
                    <measurement group_id="O5" value="378.4" lower_limit="288.7" upper_limit="496.1"/>
                    <measurement group_id="O6" value="1358.2" lower_limit="1130.0" upper_limit="1632.5"/>
                    <measurement group_id="O7" value="1721.5" lower_limit="1390.0" upper_limit="2132.1"/>
                    <measurement group_id="O8" value="379.4" lower_limit="287.9" upper_limit="500.0"/>
                    <measurement group_id="O9" value="534.2" lower_limit="417.9" upper_limit="682.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, D 0(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.3" lower_limit="138.5" upper_limit="237.4"/>
                    <measurement group_id="O2" value="210.1" lower_limit="177.0" upper_limit="249.4"/>
                    <measurement group_id="O3" value="249.0" lower_limit="217.8" upper_limit="284.7"/>
                    <measurement group_id="O4" value="197.3" lower_limit="159.0" upper_limit="244.9"/>
                    <measurement group_id="O5" value="205.5" lower_limit="161.8" upper_limit="261.1"/>
                    <measurement group_id="O6" value="237.5" lower_limit="206.4" upper_limit="273.2"/>
                    <measurement group_id="O7" value="216.5" lower_limit="181.6" upper_limit="258.2"/>
                    <measurement group_id="O8" value="198.7" lower_limit="155.2" upper_limit="254.3"/>
                    <measurement group_id="O9" value="203.7" lower_limit="165.2" upper_limit="251.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, D10(N=47;126;113;84;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="662.5" lower_limit="526.4" upper_limit="833.9"/>
                    <measurement group_id="O2" value="1564.1" lower_limit="1312.0" upper_limit="1864.7"/>
                    <measurement group_id="O3" value="1350.1" lower_limit="1142.2" upper_limit="1595.8"/>
                    <measurement group_id="O4" value="552.0" lower_limit="447.8" upper_limit="680.4"/>
                    <measurement group_id="O5" value="430.5" lower_limit="351.8" upper_limit="527.0"/>
                    <measurement group_id="O6" value="1485.0" lower_limit="1250.8" upper_limit="1763.1"/>
                    <measurement group_id="O7" value="1430.0" lower_limit="1202.3" upper_limit="1700.8"/>
                    <measurement group_id="O8" value="509.3" lower_limit="408.1" upper_limit="635.6"/>
                    <measurement group_id="O9" value="470.8" lower_limit="387.7" upper_limit="571.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, D42(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="529.3" lower_limit="426.2" upper_limit="657.2"/>
                    <measurement group_id="O2" value="1213.8" lower_limit="1004.5" upper_limit="1466.6"/>
                    <measurement group_id="O3" value="1249.3" lower_limit="1033.4" upper_limit="1510.3"/>
                    <measurement group_id="O4" value="589.4" lower_limit="469.5" upper_limit="739.9"/>
                    <measurement group_id="O5" value="377.8" lower_limit="311.3" upper_limit="458.5"/>
                    <measurement group_id="O6" value="1168.1" lower_limit="969.8" upper_limit="1407.1"/>
                    <measurement group_id="O7" value="1306.0" lower_limit="1076.8" upper_limit="1584.1"/>
                    <measurement group_id="O8" value="481.8" lower_limit="382.4" upper_limit="607.0"/>
                    <measurement group_id="O9" value="469.0" lower_limit="381.8" upper_limit="576.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.5" lower_limit="84.5" upper_limit="149.8"/>
                    <measurement group_id="O2" value="432.5" lower_limit="366.6" upper_limit="510.2"/>
                    <measurement group_id="O3" value="324.9" lower_limit="260.0" upper_limit="406.1"/>
                    <measurement group_id="O4" value="172.7" lower_limit="137.9" upper_limit="216.3"/>
                    <measurement group_id="O5" value="144.1" lower_limit="119.9" upper_limit="173.3"/>
                    <measurement group_id="O6" value="371.4" lower_limit="309.2" upper_limit="446.1"/>
                    <measurement group_id="O7" value="386.3" lower_limit="313.8" upper_limit="475.5"/>
                    <measurement group_id="O8" value="151.7" lower_limit="120.5" upper_limit="191.0"/>
                    <measurement group_id="O9" value="164.5" lower_limit="136.7" upper_limit="198.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for MN Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</title>
        <description>A seropositive subject was defined as a vaccinated subject who had a MN antibody titer ≥ the cut-off value of 1:28.</description>
        <time_frame>At Day 0, Day 10, Day 42 and Day 182</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for MN Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</title>
          <description>A seropositive subject was defined as a vaccinated subject who had a MN antibody titer ≥ the cut-off value of 1:28.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/turkey , D0(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="68"/>
                    <measurement group_id="O6" value="114"/>
                    <measurement group_id="O7" value="104"/>
                    <measurement group_id="O8" value="71"/>
                    <measurement group_id="O9" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 10(N=47;126;113;84;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="127"/>
                    <measurement group_id="O7" value="112"/>
                    <measurement group_id="O8" value="79"/>
                    <measurement group_id="O9" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 42(N=47;128;113;85;79;129;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="79"/>
                    <measurement group_id="O6" value="129"/>
                    <measurement group_id="O7" value="112"/>
                    <measurement group_id="O8" value="79"/>
                    <measurement group_id="O9" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/turkey , D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="82"/>
                    <measurement group_id="O5" value="77"/>
                    <measurement group_id="O6" value="127"/>
                    <measurement group_id="O7" value="112"/>
                    <measurement group_id="O8" value="75"/>
                    <measurement group_id="O9" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 0(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="79"/>
                    <measurement group_id="O6" value="127"/>
                    <measurement group_id="O7" value="111"/>
                    <measurement group_id="O8" value="78"/>
                    <measurement group_id="O9" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 10(N=47;126;113;84;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="127"/>
                    <measurement group_id="O7" value="112"/>
                    <measurement group_id="O8" value="79"/>
                    <measurement group_id="O9" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 42(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="129"/>
                    <measurement group_id="O7" value="112"/>
                    <measurement group_id="O8" value="79"/>
                    <measurement group_id="O9" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="83"/>
                    <measurement group_id="O5" value="78"/>
                    <measurement group_id="O6" value="128"/>
                    <measurement group_id="O7" value="112"/>
                    <measurement group_id="O8" value="78"/>
                    <measurement group_id="O9" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, D 0(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="76"/>
                    <measurement group_id="O6" value="126"/>
                    <measurement group_id="O7" value="106"/>
                    <measurement group_id="O8" value="73"/>
                    <measurement group_id="O9" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, D10(N=47;126;113;84;80;127;112;79;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="127"/>
                    <measurement group_id="O7" value="112"/>
                    <measurement group_id="O8" value="79"/>
                    <measurement group_id="O9" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, D42(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="128"/>
                    <measurement group_id="O7" value="112"/>
                    <measurement group_id="O8" value="79"/>
                    <measurement group_id="O9" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, D 182(N=47;128;113;84;79;129;112;79;84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="77"/>
                    <measurement group_id="O6" value="124"/>
                    <measurement group_id="O7" value="108"/>
                    <measurement group_id="O8" value="74"/>
                    <measurement group_id="O9" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</title>
        <description>VRR was defined as a 4-fold rise from a detectable baseline titer or a rise from undetectable (&lt; 1:28, recorded 1:14 if &lt; 1:28) to ≥ 1:56 in the subjects.</description>
        <time_frame>At Day 10</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</title>
          <description>VRR was defined as a 4-fold rise from a detectable baseline titer or a rise from undetectable (&lt; 1:28, recorded 1:14 if &lt; 1:28) to ≥ 1:56 in the subjects.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="127"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/turkey , Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="56"/>
                    <measurement group_id="O6" value="124"/>
                    <measurement group_id="O7" value="110"/>
                    <measurement group_id="O8" value="55"/>
                    <measurement group_id="O9" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="122"/>
                    <measurement group_id="O7" value="104"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="75"/>
                    <measurement group_id="O7" value="73"/>
                    <measurement group_id="O8" value="24"/>
                    <measurement group_id="O9" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains</title>
        <description>VRR was defined as a 4-fold rise from a detectable baseline titer or a rise from undetectable (&lt; 1:28, recorded 1:14 if &lt; 1:28) to ≥ 1:56 in the subjects.</description>
        <time_frame>At Day 42</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains</title>
          <description>VRR was defined as a 4-fold rise from a detectable baseline titer or a rise from undetectable (&lt; 1:28, recorded 1:14 if &lt; 1:28) to ≥ 1:56 in the subjects.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/turkey , Day 42(N=47;128;113;85;79;129;112;79;85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="58"/>
                    <measurement group_id="O6" value="122"/>
                    <measurement group_id="O7" value="109"/>
                    <measurement group_id="O8" value="56"/>
                    <measurement group_id="O9" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, D 42(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="119"/>
                    <measurement group_id="O7" value="102"/>
                    <measurement group_id="O8" value="31"/>
                    <measurement group_id="O9" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, D 42(N=47;128;113;85;80;129;112;79;86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="71"/>
                    <measurement group_id="O7" value="67"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</title>
        <description>VRR was defined as a 4-fold rise from a detectable baseline titer or a rise from undetectable (&lt; 1:28, recorded 1:14 if &lt; 1:28) to ≥ 1:56 in the subjects.</description>
        <time_frame>At Day 182</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza B1 + D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza C1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza B2 + D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza C2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza B1 + C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza D1 + E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza B2 + C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza D2 + E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine and subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine; data for both groups are pooled.
The different formulations of GSK A/turkey H5N1 Influenza vaccine were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey), A/Indonesia/5/2005 (A/Indo) and A/Vietnam/1194/2004 (A/Vie) Virus Strains.</title>
          <description>VRR was defined as a 4-fold rise from a detectable baseline titer or a rise from undetectable (&lt; 1:28, recorded 1:14 if &lt; 1:28) to ≥ 1:56 in the subjects.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom a complete set of immunogenicity data required for the primary endpoint were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="79"/>
                <count group_id="O6" value="129"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/turkey , Day 182]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="102"/>
                    <measurement group_id="O7" value="90"/>
                    <measurement group_id="O8" value="35"/>
                    <measurement group_id="O9" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indo, Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="71"/>
                    <measurement group_id="O7" value="69"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vie, Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any solicited local symptoms regardless of their intensity grade.</description>
        <time_frame>Within the 7-day (Days 0-6) post vaccination period.</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received study vaccine and for whom any post-vaccination data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza Formulation A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza Formulation B1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza Formulation B2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza Formulation C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza Formulation C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza Formulation D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza Formulation D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza Formulation E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza Formulation E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any solicited local symptoms regardless of their intensity grade.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received study vaccine and for whom any post-vaccination data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="58"/>
                <count group_id="O9" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="46"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms.</title>
        <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location (joint pain), muscle aches, shivering, sweating and fever. Any =occurrence of any solicited general symptoms reported irrespective of intensity grade and relationship to vaccination. Any fever = oral temperature ≥ 38.0 degrees Celsius (°C).</description>
        <time_frame>Within the 7-day (Days 0-6) post vaccination period.</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received study vaccine and for whom any post-vaccination data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza Formulation A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza Formulation B1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza Formulation B2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza Formulation C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza Formulation C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza Formulation D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza Formulation D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza Formulation E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza Formulation E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms.</title>
          <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location (joint pain), muscle aches, shivering, sweating and fever. Any =occurrence of any solicited general symptoms reported irrespective of intensity grade and relationship to vaccination. Any fever = oral temperature ≥ 38.0 degrees Celsius (°C).</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received study vaccine and for whom any post-vaccination data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="58"/>
                <count group_id="O9" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="23"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Joint pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Medically-attended Adverse Events (MAEs).</title>
        <description>MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any was defined as any occurrence of MAE(s).</description>
        <time_frame>From Day 0 to Day 378</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received study vaccine and for whom any post-vaccination data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza Formulation A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza Formulation B1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza Formulation B2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza Formulation C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza Formulation C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza Formulation D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza Formulation D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza Formulation E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza Formulation E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Medically-attended Adverse Events (MAEs).</title>
          <description>MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any was defined as any occurrence of MAE(s).</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received study vaccine and for whom any post-vaccination data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="61"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.“Any” was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
        <time_frame>From Day 0 to Day 42</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received study vaccine and for whom any post-vaccination data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza Formulation A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza Formulation B1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza Formulation B2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza Formulation C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza Formulation C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza Formulation D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza Formulation D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza Formulation E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza Formulation E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.“Any” was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received study vaccine and for whom any post-vaccination data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="61"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="23"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs).</title>
        <description>A SAE was defined as any untoward medical occurrence that: resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination.</description>
        <time_frame>From Day 0 to Day 378</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received study vaccine and for whom any post-vaccination data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>A/Turkey H5N1 Influenza Formulation A Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>A/Turkey H5N1 Influenza Formulation B1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>A/Turkey H5N1 Influenza Formulation B2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>A/Turkey H5N1 Influenza Formulation C1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>A/Turkey H5N1 Influenza Formulation C2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>A/Turkey H5N1 Influenza Formulation D1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>A/Turkey H5N1 Influenza Formulation D2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>A/Turkey H5N1 Influenza Formulation E1 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>A/Turkey H5N1 Influenza Formulation E2 Group</title>
            <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs).</title>
          <description>A SAE was defined as any untoward medical occurrence that: resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received study vaccine and for whom any post-vaccination data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="61"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs): During the entire study period i.e. Day 0 to Day 378; Systematically assessed adverse events (AEs): During the 7-day (Days 0-6) post vaccination period. Non-systematically assessed AE: During Days 0 – 42.</time_frame>
      <desc>For the systematically assessed other (non-serious) adverse events, the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>A/Turkey H5N1 Influenza Formulation A Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>A/Turkey H5N1 Influenza Formulation B1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>A/Turkey H5N1 Influenza Formulation B2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>A/Turkey H5N1 Influenza Formulation C1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E5">
          <title>A/Turkey H5N1 Influenza Formulation C2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E6">
          <title>A/Turkey H5N1 Influenza Formulation D1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E7">
          <title>A/Turkey H5N1 Influenza Formulation D2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E8">
          <title>A/Turkey H5N1 Influenza Formulation E1 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E9">
          <title>A/Turkey H5N1 Influenza Formulation E2 Group</title>
          <description>Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="46" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="46" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

